ASTRAZENECA PHARMA INDIA LTD. - 506820 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Please find the enclosed intimation of the Company as per the captioned subject for your reference.22-07-2023
22-07-2023
ASTRAZENECA PHARMA INDIA LTD. - 506820 - Reg. 34 (1) Annual Report.
Pursuant to Regulation 34(1) of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, please find enclosed the Annual Report of the Company for the financial year ended March 31, 2023 along with the Notice of the Annual General Meeting of the Company scheduled to be held on Monday, August 14, 2023 at 3.00 p.m. (IST) through Video Conferencing (VC)/ Other Audio Visual Means (OAVM). The Annual Report is being sent to the members who have registered their email ID with the Company/ Depositories. The Annual Report is also available on the website of the Company at www.astrazeneca.com/india.22-07-2023
ASTRAZENECA PHARMA INDIA LTD. - 506820 - Notice Of 44Th Annual General Meeting
Pursuant to Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, please find enclosed the Notice of the 44th Annual General Meeting of the Company scheduled to be held on Monday, August 14, 2023 at 3.00 p.m. (IST) through Video Conferencing (VC)/ Other Audio Visual Means (OAVM). The Notice is being sent to the Members of the Company through electronic mode. The said Notice and the Annual Report for the Financial Year ended March 31, 2023 is available on the website of the Company at www.astrazeneca.com/india.22-07-2023
ASTRAZENECA PHARMA INDIA LTD. - 506820 - Communication To The Shareholders W.R.T. TDS On Final Dividend
Please find the enclosed document of the Company as per the captioned subject for your reference.18-07-2023
ASTRAZENECA PHARMA INDIA LTD. - 506820 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
We are enclosing herewith the Certificate dated July 3, 2023 issued by Integrated Registry Management Services Private Limited, Registrar and Transfer (RTA) of the Company confirming the compliance of Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. Please take the same on record.18-07-2023
ASTRAZENECA PHARMA INDIA LTD. - 506820 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) and other applicable regulation of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Registrar and Transfer Agents of the Company, Integrated Registry Management Services Private Limited have informed the Company on the enclosed request for Loss of Share Certificate from the claimant.12-07-2023
ASTRAZENECA PHARMA INDIA LTD. - 506820 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) and other applicable regulations of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, we would like to inform you that the Registrar and Transfer Agents of the Company, Integrated Registry Management Services Private Limited have informed the Company on the enclosed request for Loss of Share Certificate from the claimant.06-07-2023
ASTRAZENECA PHARMA INDIA LTD. - 506820 - Record Date For Payment Of Dividend
Further to our intimation dated May 30, 2023, we wish to inform that the Record Date for determining the entitlement of the shareholders for the payment of the Dividend for the financial year 2022-23 is July 14, 2023. The Dividend, if approved by the shareholders, shall be paid/dispatched to the shareholders on or before September 13, 2023. This is for your kind information and records.03-07-2023
ASTRAZENECA PHARMA INDIA LTD. - 506820 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) and other applicable regulations of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Registrar and Transfer Agents of the Company, Integrated Registry Management Services Private Limited have informed the Company on the enclosed request for Loss of Share Certificate from the legal representative of the claimant.03-07-2023
AstraZeneca's cancer drug shows more potential over chemotherapy: Study
The results potentially validate Astra's decision to pay as much as $6 billion for the right to develop the medicine with Daiichi Sankyo Co. and its bet to revive growth a decade ago03-07-2023